Cargando…

Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain

AIM: The aim of this study was to develop a novel cabazitaxel bone targeted nanoparticle (NP) system for improved drug delivery to the bone microenvironment. MATERIALS & METHODS: Nanoparticles were developed using poly(D,L-lactic-co-glycolic acid) and cabazitaxel as the core with amino-bisphosph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gdowski, Andrew S, Ranjan, Amalendu, Sarker, Marjana R, Vishwanatha, Jamboor K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585843/ https://www.ncbi.nlm.nih.gov/pubmed/28805551 http://dx.doi.org/10.2217/nnm-2017-0190

Ejemplares similares

Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials
por: Gdowski, Andrew S., et al.
Publicado: (2017)

Cabazitaxel-Loaded Nanoparticles Reduce the Invasiveness in Metastatic Prostate Cancer Cells: Beyond the Classical Taxane Function
por: Lampe, Jana B., et al.
Publicado: (2023)

Development of Biodegradable Nanocarriers Loaded with a Monoclonal Antibody
por: Gdowski, Andrew, et al.
Publicado: (2015)

Optimization and scale up of microfluidic nanolipomer production method for preclinical and potential clinical trials
por: Gdowski, Andrew, et al.
Publicado: (2018)

Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy
por: Ranjan, Amalendu P, et al.
Publicado: (2012)

Novel Use of Hypoxia-Inducible Polymerizable Protein to Augment Chemotherapy for Pancreatic Cancer
por: Gdowski, Andrew, et al.
Publicado: (2022)

Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation
por: Ranjan, Amalendu P, et al.
Publicado: (2013)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
por: Colbourn, Donald
Publicado: (2012)

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
por: Mofid, Bahram, et al.
Publicado: (2015)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Uemura, Koichi, et al.
Publicado: (2018)

Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer
por: Wan, Zhong, et al.
Publicado: (2020)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
por: Patel, Sheel A, et al.
Publicado: (2017)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020)

Feasibility of cabazitaxel in octogenarian prostate cancer patients
por: Tralongo, Paolo, et al.
Publicado: (2023)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
por: Noronha, Vanita, et al.
Publicado: (2016)

Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
por: Ghosn, Marwan, et al.
Publicado: (2015)

Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges
por: Dasgupta, Subhamoy, et al.
Publicado: (2012)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
por: Delanoy, Nicolas, et al.
Publicado: (2021)

Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel
por: Meng, Fanchao, et al.
Publicado: (2019)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer
por: Qu, Na, et al.
Publicado: (2016)

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
por: Abidi, Afroz
Publicado: (2013)

Pleuropulmonary and Lymph Node Progression after Docetaxel – Benefits from Treatment with Cabazitaxel in Metastatic Prostate Cancer
por: Huerta, Angel Segura, et al.
Publicado: (2013)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
por: Bahl, A., et al.
Publicado: (2013)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)

Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2016)

Cabazitaxel Induced Thrombotic Microangiopathy in a Patient with Prostate Cancer
por: Nlandu, Yannick, et al.
Publicado: (2019)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

Preclinical profile of cabazitaxel
por: Vrignaud, Patricia, et al.
Publicado: (2014)

Tumor lysis syndrome following cabazitaxel administration for metastatic castration‐resistant prostate cancer: A case report
por: Oshima, Masashi, et al.
Publicado: (2019)

An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
por: Carles, Joan, et al.
Publicado: (2018)

Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy
por: Sun, Yating, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o0sp4anjla2a99fhn7ms519a6q